Kiniksa Pharmaceuticals Ltd
NASDAQ: KNSA · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-06-05
Kiniksa Pharmaceuticals Ltd (KNSA) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-21.87M | $-50.22M | $-81.01M | $-158.37M | $-136.53M | $-126.30M | $5.81M | $13.30M | $25.69M | $25.69M |
| Capital expenditures | $3000.00 | $69000.00 | $5.29M | $3.20M | $283000.00 | $20.41M | $105000.00 | $130000.00 | $277000.00 | $277000.00 |
| Depreciation | $22000.00 | $28000.00 | $286000.00 | $2.07M | $2.40M | $2.35M | $2.40M | $2.34M | $1.70M | — |
| Stock-based comp | $368000.00 | $897000.00 | $5.70M | $15.08M | $20.88M | $25.17M | $25.12M | $27.15M | $30.69M | $30.69M |
| Free cash flow | $-21.87M | $-50.29M | $-86.30M | $-161.57M | $-136.81M | $-146.71M | $5.70M | $13.17M | $25.41M | $25.41M |
| Investing cash flow | $-3000.00 | $-69000.00 | $-239.20M | $49.21M | $-23.44M | $128.63M | $-8.08M | $-29.56M | $37.67M | — |
| Financing cash flow | $42.51M | $39.87M | $346.74M | $84.11M | $227.09M | $5.88M | $2.52M | $1.50M | $12.27M | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $26.53M | $-25.05M | $67.11M | $8.22M | $245000.00 | — | — | — |
Frequently asked questions
What is Kiniksa Pharmaceuticals Ltd's revenue?
Kiniksa Pharmaceuticals Ltd's trailing twelve-month revenue is $754.04M, and consensus projects about $2.16B by 2030. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is KNSA?
In its most recent fiscal year, KNSA ran a gross margin of 54.63%, an operating margin of 11.40%, and a net margin of 8.71%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does KNSA generate?
KNSA produced $25.41M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is KNSA's balance sheet healthy?
KNSA holds $165.60M in cash and equivalents against — in long-term debt, on $567.61M of shareholder equity. That debt is best read against the cash flow the business throws off each year.